Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004

British Journal of Clinical Pharmacology

Volumn 61, Issue 2, 2006, Pages 224-228

  Martin, Richard M ^a   May, Margaret ^a   Gunnell, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adverse events; Media; Paroxetine; Selective serotonin reuptake inhibitors; Time trends

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; DATA BASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; STEADY STATE; TIME SERIES ANALYSIS; UNITED KINGDOM; UNITED STATES; WITHDRAWAL SYNDROME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DATABASES; ENGLAND; FAMILY PRACTICE; HUMANS; MASS MEDIA; PAROXETINE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SEROTONIN UPTAKE INHIBITORS;

EID: 33644926685     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02527.x     Document Type: Article

References (11)

1. Tonks A Withdrawal from paroxetine can be severe, warns FDA BMJ 2002 324 260
2. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants London Committee on Safety of Medicines 2004
3. Gunnell D Ashby D Antidepressants and suicide: what is the balance of benefit and harm BMJ 2004 329 34 8
4. Kim HJ Fay MP Feuer EJ Midthune DN Permutation tests for joinpoint regression with applications to cancer rates Statistics Med 2000 19 335 51
5. Lerman PM Fitting segmented regression models by grid search Appl Stat 1980 29 77 84
6. Pacheco L Malo P Aragues E Etxebeste M More cases of paroxetine withdrawal syndrome Br J Psychiatry 1996 169 384
7. Diler RS Tamam L Avci A Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy J Clin Psychopharmacol 2000 20 586 7
8. Committee on Safety of Medicines/Medicines Control Agency. Selective serotonin reuptake inhibitors Current Problems Pharmacovigilance 2000 26 11 2
9. Price JS Waller PC Wood SM MacKay AV A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal Br J Clin Pharmacol 1996 42 757 63
10. Stahl MM Lindquist M Pettersson M Edwards IR Sanderson JH Taylor NF Fletcher AP Schou JS Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system Eur J Clin Pharmacol 1997 53 163 9
11. Waller PC Evans SJ A model for the future conduct of pharmacovigilance Pharmacoepidemiol Drug Safety 2003 12 17 29